FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Jones

Research Profile

Chemicals & Drugs

Disorders

Procedures

Drug Therapy, Combination

Concepts & Ideas

Treatment Outcome

Co-author Network

Publications

TOP 3
Smita I Negi; Eliana Polisecki; Ernst J Schaefer; Salim S Virani; Aashish Anand; Bela F Asztalos; Christie M Ballantyne; Ariel Brautbar; Peter H Jones
A novel mutation in the ABCA1 gene causing an atypical phenotype of Tangier disease.
Peter H Jones; Radhika Nair; Kamlesh M Thakker
Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.
Smita I Negi; Laura A Petersen; Venkateshwar R Polsani; Lynne Steinberg; Christie M Ballantyne; Saqib A Gowani; Peter H Jones; Varinder Kumar; Victor Marinescu; Vijay Nambi; Salim S Virani
Non-high-density lipoprotein cholesterol calculation and goal awareness among physicians-in-training.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Jones (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Smita I Negi; Eliana Polisecki; Ernst J Schaefer; Salim S Virani; Aashish Anand; Bela F Asztalos; Christie M Ballantyne; Ariel Brautbar; Peter H Jones
A novel mutation in the ABCA1 gene causing an atypical phenotype of Tangier disease.
Journal of clinical lipidology 2013;7(1):82-7.
2012: Peter H Jones; Radhika Nair; Kamlesh M Thakker
Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.
Journal of the American Heart Association 2012;1(6):e001800.
2012: Smita I Negi; Laura A Petersen; Venkateshwar R Polsani; Lynne Steinberg; Christie M Ballantyne; Saqib A Gowani; Peter H Jones; Varinder Kumar; Victor Marinescu; Vijay Nambi; Salim S Virani
Non-high-density lipoprotein cholesterol calculation and goal awareness among physicians-in-training.
Journal of clinical lipidology 2012;6(1):50-7.
2011: Ariel Brautbar; Daniel Covarrubias; Peter H Jones; Fremiet Lara-Garduno; Suzanne M Leal; Salim S Virani; John Belmont; Christie M Ballantyne
Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
Atherosclerosis 2011;219(2):737-42.
2011: Christie M Ballantyne; Peter H Jones; Maureen T Kelly; Carolyn M Setze; Aditya Lele; Kamlesh M Thakker; James C Stolzenbach
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2011;25(1):59-67.
2010: Peter H Jones; Anne C Goldberg; Howard R Knapp; Maureen T Kelly; Carolyn M Setze; James C Stolzenbach; Darryl J Sleep
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
American heart journal 2010;160(4):759-66.
2010: Peter H Jones
Treating dyslipidemia in the high-risk patient.
The Journal of family practice 2010;59(2):E1.
2010: Peter H Jones
Update on lipids and C-reactive protein in acute and chronic coronary heart disease.
Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital 2010;37(3):307-8.
2010: Peter H Jones; Kenneth Cusi; Michael H Davidson; Maureen T Kelly; Carolyn M Setze; Kamlesh Thakker; Darryl J Sleep; James C Stolzenbach
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2010;10(2):73-84.
2009: Venkateshwar R Polsani; Vijay Nambi; Salim S Virani; Danièle Zoch; Eric Y Yang; Peter H Jones; Christie M Ballantyne
Efficacy and tolerability of multidrug therapy for hypertriglyceridemia.
Journal of clinical lipidology 2009;3(5):341-4.
2009: Peter H Jones; Michael H Davidson; Moti L Kashyap; Maureen T Kelly; Susan M Buttler; Carolyn M Setze; Darryl J Sleep; James C Stolzenbach
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
Atherosclerosis 2009;204(1):208-15.
2009: Peter H Jones; Michael H Davidson; Anne C Goldberg; Carl J Pepine; Maureen T Kelly; Susan M Buttler; Carolyn M Setze; Aditya Lele; Darryl J Sleep; James C Stolzenbach
Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies.
Journal of clinical lipidology 2009;3(2):125-37.
2008: Peter H Jones
Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
The American journal of cardiology 2008;102(12A):41L-47L.
2008: Peter H Jones; John A Farmer
Adjunctive interventions in myocardial infarction: the role of statin therapy.
Current atherosclerosis reports 2008;10(2):142-8.
2008: Venkateshwar R Polsani; Peter H Jones; Christie M Ballantyne; Vijay Nambi
A case report of myopathy from consumption of red yeast rice.
Journal of clinical lipidology 2008;2(1):60-2.
2008: Peter H Jones; Harold E Bays; Michael H Davidson; Maureen T Kelly; Susan M Buttler; Carolyn M Setze; Darryl J Sleep; James C Stolzenbach
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Clinical drug investigation 2008;28(10):625-34.
2007: James M McKenney; Peter H Jones; Harold E Bays; Robert H Knopp; Moti L Kashyap; Gary E Ruoff; Mark E McGovern
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
Atherosclerosis 2007;192(2):432-7.
2007: Peter H Jones
Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
The American journal of cardiology 2007;99(4A):133B-140B.
2006: Peter H Jones
Dyslipidemia in older adults.
The American journal of geriatric cardiology 2006;15(4):239-44.
2006: Nicole E Jelesoff; Christie M Ballantyne; Antonios M Xydakis; Philip Chiou; Peter H Jones; John R Guyton
Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2006;12(2):159-64.
2006: Ryan C Neal; Peter H Jones
Complementary therapy to target LDL cholesterol: the role of the ezetimibe/simvastatin combination.
Vascular health and risk management 2006;2(1):31-8.
2006: Peter H Jones
Lipids: new guidelines, intensive treatment, and future directions.
Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital 2006;33(2):180-3.
2006: Peter H Jones
Rationale for intensive statin treatment in high-risk patients.
Preventive cardiology 2006;9(2):91-5.
2006: Abu R Vasudevan; Peter H Jones
Effective use of combination lipid therapy.
Current atherosclerosis reports 2006;8(1):76-84.
2006: Abu R Vasudevan; Huaizhu Wu; Antonios M Xydakis; Peter H Jones; E O'Brian Smith; John F Sweeney; David B Corry; Christie M Ballantyne
Eotaxin and obesity.
The Journal of clinical endocrinology and metabolism 2006;91(1):256-61.
2005: Abu R Vasudevan; Yasmin S Hamirani; Peter H Jones
Safety of statins: effects on muscle and the liver.
Cleveland Clinic journal of medicine 2005;72(11):990-3, 996-1001.
2005: Abu R Vasudevan; Peter H Jones
Effective use of combination lipid therapy.
Current cardiology reports 2005;7(6):471-9.
2005: Peter H Jones
Statins: the case for higher, individualized starting doses.
Cleveland Clinic journal of medicine 2005;72(9):811-6.
2005: Mine Y Liu; Antonios M Xydakis; Ron C Hoogeveen; Peter H Jones; E O'Brian Smith; Kathleen W Nelson; Christie M Ballantyne
Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system.
Clinical chemistry 2005;51(7):1102-9.
2005: Prakash C Deedwania; Donald B Hunninghake; Harold E Bays; Peter H Jones; Valerie A Cain; James W Blasetto
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
The American journal of cardiology 2005;95(3):360-6.
2005: Peter H Jones; James M McKenney; Dean G Karalis; Jackson Downey
Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.
American heart journal 2005;149(1):e1.
2005: Peter H Jones; Michael H Davidson
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
The American journal of cardiology 2005;95(1):120-2.
2004: Antonios M Xydakis; John R Guyton; Philip Chiou; Judy L Stein; Peter H Jones; Christie M Ballantyne
Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia.
The American journal of cardiology 2004;94(6):795-7.
2004: Peter H Jones; Donald B Hunninghake; Keith C Ferdinand; Evan A Stein; Alex Gold; Richard J Caplan; James W Blasetto
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Clinical therapeutics 2004;26(9):1388-99.
2004: Antonios M Xydakis; Christopher C Case; Peter H Jones; Ron C Hoogeveen; Mine-Yine Liu; E O'Brian Smith; Kathleen W Nelson; Christie M Ballantyne
Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction.
The Journal of clinical endocrinology and metabolism 2004;89(6):2697-703.
2004: Peter H Jones
Low-density lipoprotein cholesterol reduction and cardiovascular disease prevention: the search for superior treatment.
The American journal of medicine 2004;116 Suppl 6A():17S-25S.
2004: Ashok Balasubramanyam; Rajagopal V Sekhar; Farook Jahoor; Peter H Jones; Henry J Pownall
Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis'.
Current opinion in lipidology 2004;15(1):59-67.
2003: Ryan C Neal; Peter H Jones
Lipid-lowering: can ezetimibe help close the treatment gap?
Cleveland Clinic journal of medicine 2003;70(9):777-83.
2003: Antonios M Xydakis; Peter H Jones
Toxicity of antilipidemic agents: facts and fictions.
Current atherosclerosis reports 2003;5(5):403-10.
2003: Peter H Jones
Achieving cholesterol goals. Current and future drug therapies.
Postgraduate medicine 2003;114(2 Suppl):14-21.
2003: Peter H Jones
Atherosclerosis target of lipid-lowering therapy: is lower LDL cholesterol better?
The American journal of managed care 2003;Suppl():1, 4-5.
2003: Peter H Jones; Michael H Davidson; Evan A Stein; Harold E Bays; James M McKenney; Elinor Miller; Valerie A Cain; James W Blasetto
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
The American journal of cardiology 2003;92(2):152-60.
2003: Peter H Jones
Cholesterol and coronary events. The current thinking.
Postgraduate medicine 2003;113(4 Suppl):5-14.
2003: James M McKenney; Peter H Jones; M Angeli Adamczyk; Valerie A Cain; Brian S Bryzinski; James W Blasetto
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
Current medical research and opinion 2003;19(8):689-98.
2003: Peter H Jones
Comparing HMG-CoA reductase inhibitors.
Clinical cardiology 2003;26(1 Suppl 1):I15-20.
2002: Christopher C Case; Peter H Jones; K Nelson; E O'Brian Smith; Christie M Ballantyne
Impact of weight loss on the metabolic syndrome.
Diabetes, obesity & metabolism 2002;4(6):407-14.
2002: Peter H Jones
The power of statins: aggressive lipid lowering.
Postgraduate medicine 2002;112(4 Suppl):23-30.
2001: Juan Carlos Plana; Peter H Jones
The use of statins in acute coronary syndromes: the mechanisms behind the outcomes.
Current atherosclerosis reports 2001;3(5):355-64.
2000: Peter H Jones
Diet and pharmacologic therapy of obesity to modify atherosclerosis.
Current atherosclerosis reports 2000;2(4):314-20.
2000: Peter H Jones
The nature of the statins.
Circulation 2000;101(8):E89.
1999: Peter H Jones
Web alert.
Current cardiology reports 1999;1(3):175-6.
1999: Peter H Jones
Fibrates and high-dose statins to prevent coronary heart disease events.
Current cardiology reports 1999;1(3):223-4.
1999: Christie M Ballantyne; J Alan Herd; LL Ferlic; J Kay Dunn; John A Farmer; Peter H Jones; J R Schein; Antonio M Gotto
Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy.
Circulation 1999;99(6):736-43.
1998: Peter H Jones
Future of lipid-lowering trials: what else do we need to know?
The American journal of cardiology 1998;82(6A):32M-38M.
1997: C M Ballantyne; J Alan Herd; J Kay Dunn; Peter H Jones; John A Farmer; Antonio M Gotto
Effects of lipid lowering therapy on progression of coronary and carotid artery disease.
Current opinion in lipidology 1997;8(6):354-61.
1997: J Alan Herd; Christie M Ballantyne; John A Farmer; J J Ferguson; Peter H Jones; M S West; K L Gould; Antonio M Gotto
Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]).
The American journal of cardiology 1997;80(3):278-86.
1996: Peter H Jones; Henry J Pownall; Wolfgang Patsch; J Alan Herd; John A Farmer; C Payton-Ross; Kay T Kimball; Antonio M Gotto; Joel D Morrisett
Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects.
Journal of lipid research 1996;37(6):1298-308.
1995: Peter H Jones
Trials of lipid-lowering therapy in primary prevention of coronary heart disease.
Current opinion in lipidology 1995;6(6):365-8.
1995: Peter H Jones; Antonio M Gotto
Extending the benefit of lipid-regulating therapy to primary prevention.
The American journal of cardiology 1995;76(9):118C-121C.
1994: J A Quion; Peter H Jones
Clinical pharmacokinetics of pravastatin.
Clinical pharmacokinetics 1994;27(2):94-103.
1992: John A Farmer; L C Washington; Peter H Jones; D R Shapiro; Antonio M Gotto; G Mantell
Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants.
Clinical therapeutics 1992;14(5):708-17.
1992: Christie M Ballantyne; Branislav Radovancevic; John A Farmer; O Howard Frazier; L Chandler; C Payton-Ross; B Cocanougher; Peter H Jones; J B Young; Antonio M Gotto
Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations.
Journal of the American College of Cardiology 1992;19(6):1315-21.
1991: Peter H Jones; John A Farmer; M D Cressman; J M McKenney; J T Wright; J D Proctor; D M Berkson; D J Farnham; P M Wolfson; H T Colfer
Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study.
Clinical cardiology 1991;14(2):146-51.
1990: Peter H Jones
Lovastatin and simvastatin prevention studies.
The American journal of cardiology 1990;66(8):39B-43B.
1988: C L Corpier; Peter H Jones; W N Suki; Eleanor DeLand Lederer; M A Quinones; S W Schmidt; J B Young
Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.
JAMA : the journal of the American Medical Association 1988;260(2):239-41.
1987: Christie M Ballantyne; Peter H Jones; C Payton-Ross; W Patsch; H D Short; George P Noon; Antonio M Gotto; M E DeBakey; J B Young
Hyperlipidemia following heart transplantation: natural history and intervention with mevinolin (lovastatin).
Transplantation proceedings 1987;19(4 Suppl 5):60-2.